Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

company dedicated tounlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit [www.quincetx.com] and follow Quince on social media platforms [LinkedIn], [Facebook], [X], and [YouTube].Forward-looking StatementsStatements in this news release contain "forward-looking statements†within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, ...